Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine

Timo Vesikari, David O. Matson, Penelope Dennehy, Pierre Van Damme, Mathuram Santosham, Zoe Rodriguez, Michael J. Dallas, Joseph F. Heyse, Michelle G. Goveia, Steven B. Black, Henry R. Shinefield, Celia D.C. Christie, Samuli Ylitalo, Robbin F. Itzler, Michele L. Coia, Matthew T. Onorato, Ben A. Adeyi, Gary S. Marshall, Leif Gothefors, Dirk CampensAino Karvonen, James P. Watt, Katherine L. O'Brien, Mark J. DiNubile, H. Fred Clark, John W. Boslego, Paul A. Offit, Penny M. Heaton

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Rotavirus is a leading cause of childhood gastroenteritis and death worldwide. METHODS: We studied healthy infants approximately 6 to 12 weeks old who were randomly assigned to receive three oral doses of live pentavalent human-bovine (WC3 strain) reassortant rotavirus vaccine containing human serotypes G1, G2, G3, G4, and P[8] or placebo at 4-to-10-week intervals in a blinded fashion. Active surveillance was used to identify subjects with serious adverse and other events. RESULTS: The 34,035 infants in the vaccine group and 34,003 in the placebo group were monitored for serious adverse events. Intussusception occurred in 12 vaccine recipients and 15 placebo recipients within one year after the first dose including six vaccine recipients and five placebo recipients within 42 days after any dose (relative risk, 1.6; 95 percent confidence interval, 0.4 to 6.4). The vaccine reduced hospitalizations and emergency department visits related to G1-G4 rotavirus gastroenteritis occurring 14 or more days after the third dose by 94.5 percent (95 percent confidence interval, 91.2 to 96.6 percent). In a nested substudy, efficacy against any G1-G4 rotavirus gastroenteritis through the first full rotavirus season after vaccination was 74.0 percent (95 percent confidence interval, 66.8 to 79.9 percent); efficacy against severe gastroenteritis was 98.0 percent (95 percent confidence interval, 88.3 to 100 percent). The vaccine reduced clinic visits for G1-G4 rotavirus gastroenteritis by 86.0 percent (95 percent confidence interval, 73.9 to 92.5 percent). CONCLUSIONS: This vaccine was efficacious in preventing rotavirus gastroenteritis, decreasing severe disease and health care contacts. The risk of intussusception was similar in vaccine and placebo recipients. (ClinicalTrials.gov number, NCT00090233.)

Original languageEnglish (US)
Pages (from-to)23-33
Number of pages11
JournalNew England Journal of Medicine
Volume354
Issue number1
DOIs
StatePublished - May 1 2006

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine'. Together they form a unique fingerprint.

Cite this